MELANOMA: tratamiento de primera línea - page 2

Evolución del tratamiento del melanoma metastásico
aDate of first approval in the United States or European Union. IPI, ipilimumab; NIVO, nivolumab.
1. DeVita VT Jr, et al. Cancer Res. 2008;68:8643-8653. 2. American Cancer Society. The history of cancer.http://www.cancer.org/cancer/cancerbasics/thehistoryofcancer/. 3. Finn OJ. Ann
Oncol. 2012;23(suppl 8):viii6-viii9. 4. Mansh M. Yale J Biol Med. 2011;84:381-389. 5. Kirkwood JM, et al. CA Cancer J Clin. 2012;62:309-335. 6. NCI Cancer Drug Information.
Vemurafenib. http://www.cancer.gov/cancertopics/druginfo/vemurafenib.7. NCI Cancer Drug Information. Dabrafenib.http://www.cancer.gov/cancertopics/druginfo/dabrafenib.8. NCI
Cancer Drug Information. Trametinib.http://www.cancer.gov/cancertopics/druginfo/trametinib. 9. FDA Press Release. December 22, 2014
http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm427807.htm accessed 9 March, 2015. 10. FDA. Approved drugs: pembrolizumab. September 4, 2014.
http://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm412861.htm; 11. ASCO press release 10 Jan, 2014. 12. BMS Press Release 1 October, 2015.
Surgery
1846
Radiation Therapy
1901
Chemotherapy
1946
Targeted Therapy
Vemurafenib 2011 a
Trametinib 2013 a
Dabrafenib 2013a
Dabrafenib + trametinib 2014a
Vemurafenib + Cobimetinib 2015
Immuno-Oncology
Ipilimumab 2011a
Nivolumab 2014a
Pembrolizumab 2014a
Nivolumab+ Ipilimumab 2015a
Immunotherapy
Interferon-α 1995a
Interleukin-2 1998a
BRAF status ??
Chemotherapy